In most solid tumours, PD‐L1 expression levels in the tumour determine whether a patient receives anti‐PD1 immune checkpoint inhibitors, with data showing that higher levels of PD‐L1 expression correlate with better response. The gene discussed is CD274; the disease is neoplasm.